A startup launched just 15 months ago by a former senior vice president of early stage programs at Biogen has just sold to New Jersey drug giant Bristol-Myers Squibb for $225 million up front and in near-term payments, plus another $375 million in milestone payments.

press release from Bristol-Myers
article in Boston Business Journal
article in FierceBiotech